Cohort of patients with metastatic colorectal cancer initiating a chemotherapy in combination with Avastin® FRESH-PEF74088-en Camille BACHOT Cohort of patients with metastatic colorectal cancer initiating a chemotherapy in combination with Avastin® CONCERT FRESH-PEF74088-en 74088 FRESH-PEF74088 NCT02612077 F. HOFFMANN-LA ROCHE AG Epidemiology France Portal (PEF) null ;Medical data center bevacizumab Oncology Gastroenterology Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues Healthcare system determinants: Use of care Healthcare system determinants Primary Objective: To assess in real life the Progression-Free Survival at a maximum of 36 months follow-up, in patients suffering from metastatic colorectal cancer and initiating a treatment with Avastin® combined with chemotherapy. Secondary Objectives: - To describe characteristics of patients treated with Avastin® - To describe the use of Avastin® over the study period - To assess the overall survival of patients treated with Avastin® - To describe the Avastin® safety profile (serious adverse events and/or unexpected related to Avastin®, and/or adverse events of special interest) - To describe the quality of life of patients treated with Avastin®. Exploratory Objective: A search for the prognostic factors of PFS and OS was performed using a Cox model in patients treated with 1st line of chemotherapy (overall and in the subgroup of patients with synchronous metastases). These factors were determined from the characteristics of patients at inclusion. null France Individuals Patients population Male Female Young Adult (19 to 24 years) Adult (25 to 44 years) Middle Aged (45 to 64 years) Aged (65 to 79 years) Aged, 80 and over (80 years and more) Inclusion criteria: - Adult patient (aged >= 18 years) - Patient suffering from metastatic colic or rectal carcinoma for which the physician decided to start a treatment with Avastin® combined with chemotherapy, at the inclusion time - Patient who received about the study both oral and written information and who did not object to his/her personal data being processed Participation in a clinical trial designed to assess a cytotoxic anticancer treatment and/or an innovative therapy Clinical data Participant-reported health data CDISC like GCP/GVP Other Through independent healthcare practitioners [500-1000[ individuals Interview with the participant (including clinical) Observational Study Observational Study 765 Unknown Restricted access Access on specific project only